Foresee Pharmaceuticals Co.

Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium

by

TAIPEI, Taiwan, Sept. 30, 2023 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study (FuschiA study) currently being initiated, at the Fanconi Anemia Research Fund (FARF) 2023 Scientific Symposium taking place in Vancouver, BC, Canada from September … Read more

Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023

by

Late-breaking oral presentation on the positive primary outcomes of aderamastat, a first-in-class, oral MMP-12 inhibitor in a Phase 2 Phase 2 proof-of-concept allergic asthma study, supporting potential novel anti-inflammatory mechanism for respiratory diseases. TAIPEI, Sept. 12, 2023 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company presented the positive primary outcomes of … Read more

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs) USA – English USA – English

by

Mice with a conditional deletion of the Tsc2 gene in CD11c+ cells leading to chronic activation of mTORC1 signaling in myeloid cells, caused spontaneous cardiac sarcoid-like granulomas. Inhibiting MMP-12 with FP-020 attenuated macrophage infiltration, macrophage clustering, decreased fibrotic replacement, and reduced the number of activated fibroblasts. MMP-12 might therefore be required for granuloma formation and persistence, and further … Read more

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs) USA – English USA – English

by

Mice with a conditional deletion of the Tsc2 gene in CD11c+ cells leading to chronic activation of mTORC1 signaling in myeloid cells, caused spontaneous cardiac sarcoid-like granulomas. Inhibiting MMP-12 with FP-020 attenuated macrophage infiltration, macrophage clustering, decreased fibrotic replacement, and reduced the number of activated fibroblasts. MMP-12 might therefore be required for granuloma formation and persistence, and further … Read more

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

by

Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism TAIPEI, June 16, 2023 /PRNewswire/ — Foresee Pharmaceuticals (6576.TWO), (“Foresee”) announced today that the company will be participating and presenting a poster at the WASOG 2023 … Read more